Galmed Pharmaceuticals EBIT

Galmed Pharmaceuticals (GLMD) currently reports a EBIT of $-9.3M as of March 2026. That compares with $-7.7M in the prior-year period — down 20.6% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Galmed Pharmaceuticals's EBIT history and peer comparisons.

Galmed Pharmaceuticals's EBIT decreased from $-7.7M to $-9.3M — a 20.6% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Galmed Pharmaceuticals's EBIT of $-9.3M is lower than the Healthcare sector average of $22B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Galmed Pharmaceuticals reported $-9.3M in EBIT as of March 2026. That compares with $-7.7M in the prior-year period — down 20.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-9.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Galmed Pharmaceuticals, and consider following GLMD for alerts when major investors trade the stock.